stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) Return on equity
GSK PLC Sponsored ADR's return on equity over the twelve months to 30 September 2026 was 25.5%, down 14.4 percentage points from fiscal 2025 (39.9%). Over the past ten years it has ranged from 12.2% (fiscal 2016) to 118.6% (fiscal 2015); the current reading is higher than 55% of that period. That is above the Drug Manufacturers General industry median of 5.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 39.9% | 19.76 |
| FY2024 | 20.2% | (23.00) |
| FY2023 | 43.2% | (45.28) |
| FY2022 | 88.4% | 66.93 |
| FY2021 | 21.5% | (7.92) |
| FY2020 | 29.4% | (12.43) |
| FY2019 | 41.9% | (61.05) |
| FY2018 | 102.9% | 67.72 |
| FY2017 | 35.2% | 23.01 |
| FY2016 | 12.2% | (106.45) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| AMGN Amgen Inc. compare | 78.4% |
| NVO Novo Nordisk A/S compare | 60.8% |
| BMY Bristol Myers Squibb Company compare | 44.0% |
| GSK GSK PLC Sponsored ADR | 25.5% |
| AZN AstraZeneca PLC compare | 22.6% |
| PFE Pfizer Inc. compare | 4.42% |
| BIIB Biogen Inc. compare | 1.87% |
| SNY Sanofi compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −22.5% |
| Drug Manufacturers General industry median | 5.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on GSK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement